Taro Pharmaceutical Industries Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is OXICONAZOLE NITRATE, MICRONIZED, with a corresponding US DMF Number 26226.
Remarkably, this DMF maintains an Active status since its submission on November 28, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 15, 2013, and payment made on November 06, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II